Ascentage Pharma showcases novel drug candidates at AACR 2024
Ascentage Pharma (6855.HK), a prominent global biopharmaceutical firm, recently unveiled the latest preclinical study results for its innovative drug candidates at the American Association of Cancer Research Annual Meeting (AACR 2024) held in San Diego, California. This pivotal revelation underscores the company’s continued dedication to pioneering novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, marking a significant stride in clinical development.
At the forefront of medical innovation, Ascentage Pharma’s recent disclosure at AACR 2024 highlights the company’s ongoing efforts to address some of the most pressing challenges in oncology and chronic diseases. Among the notable advancements are the preclinical results of olverembatinib, alrizomadlin (APG-115), APG-2449, and APG-5918, showcasing potential breakthroughs in the treatment of succinate dehydrogenase (SDH)-deficient neoplasms, prostate cancer, and ovarian cancer, respectively.
Olverembatinib, a novel multikinase inhibitor, has demonstrated superior antitumor activity in SDH-deficient neoplasms, offering hope for patients with gastrointestinal stromal tumor (GIST), paraganglioma, pheochromocytoma, among others. This promising efficacy, underpinned by the modulation of multiple signaling pathways, lays the groundwork for future clinical development in dSDH cancers.
Moreover, the synergistic inhibition of tumor growth by the embryonic ectoderm development (EED) inhibitor APG-5918 and MDM2 inhibitor alrizomadlin (APG-115) in prostate cancer models paves the way for novel therapeutic strategies in combating castration-resistant prostate cancer (CRPC). This combination’s enhanced antitumor activity signifies a leap forward in addressing the unmet medical needs of PCa patients.
In the realm of epithelial ovarian cancer (EOC), APG-2449, a novel focal adhesion kinase (FAK) inhibitor, combined with PEGylated liposome doxorubicin (PLD), has shown promising results in inhibiting metastasis and improving antitumor efficacy. This innovative approach could revolutionize the treatment paradigm for ovarian cancer, particularly in platinum-resistant cases.
Founded with a mission to develop therapeutics that inhibit protein-protein interactions to restore apoptosis, Ascentage Pharma has rapidly emerged as a leader in the biopharmaceutical industry. With a robust pipeline of clinical drug candidates and over 40 Phase I/II clinical trials underway across the globe, the company is at the cutting edge of addressing critical medical conditions through innovative therapies.
Ascentage Pharma’s commitment to leveraging its robust R&D capabilities is evident in its portfolio of global intellectual property rights and strategic partnerships with leading institutions. The company’s success in securing Priority Review, Breakthrough Therapy Designations, and Orphan Drug Designations from major regulatory bodies further validates the potential of its drug candidates to meet urgent clinical needs worldwide.
In conclusion, Ascentage Pharma’s revelations at AACR 2024 represent a beacon of hope for patients with cancer, chronic hepatitis B, and age-related diseases. Through its relentless pursuit of medical breakthroughs, Ascentage Pharma is poised to redefine treatment standards and improve patient outcomes globally, embodying the true spirit of innovation in healthcare.